Clinical Trial Update: A Dose Per Fraction Escalation Trial of Hypofractionated IMRT With Temozolomide for Newly Diagnosed Glioblastoma [Phase 1]

View source ↗

Summary

This Phase 1 trial investigates a dose-per-fraction escalation of hypofractionated IMRT with temozolomide for newly diagnosed glioblastoma and has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma Multiforme

Drugs mentioned

• Temodar (Temozolomide)

Snippet

Sponsor: University of Colorado, Denver | Conditions: Glioblastoma Multiforme | Phase 1 | Status: COMPLETED